CERo Therapeutics Company Leadership
| CERO Stock | 0.06 0.01 19.00% |
CERo Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding CERo Therapeutics Holdings, suggests that virtually all insiders are panicking. CERo Therapeutics employs about 8 people. The company is managed by 7 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.14 employees per reported executive.
CERo Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-12-09 | Bioventures Opportunities G Yk | Disposed 850543 @ 0.11 | View | ||
| 2024-12-06 | Bioventures Opportunities G Yk | Disposed 1236874 @ 0.12 | View | ||
| 2024-10-10 | Bioventures Opportunities G Yk | Disposed 3250000 @ 0.1 | View | ||
| 2024-09-25 | Stuart M Sloan | Disposed 532486 @ 0.1 | View |
Monitoring CERo Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
CERo |
CERo Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4528) % which means that it has lost $0.4528 on every $100 spent on assets. This is way below average. CERo Therapeutics' management efficiency ratios could be used to measure how well CERo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Equity is likely to grow to 0.0002, while Return On Tangible Assets are likely to drop (0.0003). At this time, CERo Therapeutics' Other Current Assets are very stable compared to the past year. As of the 13th of December 2024, Debt To Assets is likely to grow to 0.19, while Total Assets are likely to drop about 8.1 M.As of the 13th of December 2024, Common Stock Shares Outstanding is likely to grow to about 9.7 M
CERo Therapeutics Workforce Comparison
CERo Therapeutics Holdings, is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 24,809. CERo Therapeutics adds roughly 8.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CERo Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CERo Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on CERo Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CERo Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yk Bioventures Opportunities Gp I, Llc a day ago Disposition of 1614541 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.07 subject to Rule 16b-3 | ||
Yk Bioventures Opportunities Gp I, Llc 3 days ago Disposition of 1570947 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.09 subject to Rule 16b-3 | ||
Yk Bioventures Opportunities Gp I, Llc few days ago Disposition of 850543 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.11 subject to Rule 16b-3 | ||
Patel Shami over a week ago Acquisition by Patel Shami of 127500 shares of CERo Therapeutics at 0.0951 subject to Rule 16b-3 | ||
Patel Shami over two months ago Insider Trading | ||
Kristen Pierce over two months ago Insider Trading | ||
Brian Atwood over two months ago Disposition of 1317956 shares by Brian Atwood of CERo Therapeutics at 1.77 subject to Rule 16b-3 | ||
Laporte Kathleen over three months ago Acquisition by Laporte Kathleen of 5828 shares of CERo Therapeutics subject to Rule 16b-3 |
CERo Therapeutics Notable Stakeholders
A CERo Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CERo Therapeutics often face trade-offs trying to please all of them. CERo Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CERo Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Daniel MD | CTO Founder | Profile | |
| Lawrence MD | Cofounder Board | Profile | |
| Christopher MBA | Interim Chairman | Profile | |
| Brian Atwood | President Director | Profile | |
| Charles Carter | Treasurer CFO | Profile | |
| Kristen Pierce | Chief Director | Profile | |
| Andrew MBA | Chief Officer | Profile |
About CERo Therapeutics Management Performance
The success or failure of an entity such as CERo Therapeutics often depends on how effective the management is. CERo Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CERo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CERo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.87) | (0.82) |
CERo Therapeutics Workforce Analysis
Traditionally, organizations such as CERo Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CERo Therapeutics within its industry.CERo Therapeutics Manpower Efficiency
Return on CERo Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 317 | |
| Net Loss Per Executive | 362 | |
| Working Capital Per Employee | 739K | |
| Working Capital Per Executive | 844.6K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.